Ascentage Pharma Group International – Unsponsored ADR’s (NASDAQ:AAPG) Lock-Up Period Set To End on July 23rd

Ascentage Pharma Group International’s (NASDAQ:AAPG) lock-up period will end on Wednesday, July 23rd. Ascentage Pharma Group International had issued 7,325,000 shares in its public offering on January 24th. The total size of the offering was $126,356,250 based on an initial share price of $17.25. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Analyst Ratings Changes

Separately, JPMorgan Chase & Co. initiated coverage on shares of Ascentage Pharma Group International in a research note on Thursday, March 27th. They issued an “overweight” rating for the company.

Ascentage Pharma Group International Price Performance

NASDAQ:AAPG opened at $36.76 on Wednesday. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 3.24. The stock’s 50-day simple moving average is $31.66. Ascentage Pharma Group International has a one year low of $16.50 and a one year high of $43.58.

Institutional Investors Weigh In On Ascentage Pharma Group International

An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new position in shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 159,942 shares of the company’s stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent reporting period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.